VolitionRx Limited (NYSEAMERICAN:VNRX) is unveiling a new epigenetic toolbox thanks to new research on its Nu.Q Capture program.
The Austin, Texas-based company said Tuesday that research on its Nu.Q program led to the development of a suite of novel epigenetic tools for cancer diagnostics.
The research builds upon breakthroughs on Volition’s assay platform that it announced last month.
The new tools could usher in a paradigm shift in epigenetic-based blood tests, according to Dr Mark Eccleston, one of Volition’s founding scientists and its business development director. Eccleston also told shareholders that the tools will help Volition establish a leadership position in the epigenetics diagnostics field.
Nu.Q Capture technologies have emanated from years of focused research in clinical epigenetics, Volition’s chief scientific officer Dr Jake Micallef told shareholders.
“We have filed several patents relating to these Nu.Q methods to add to Volition's already extensive patent portfolio, with the aim of securing broad coverage and protection in this key area of epigenetics,” Micallef said in a statement.
Volition has filed patent applications on the Nu.Q tools, in addition to its bead-based Nu.Q assay format, to decipher the epigenetic and environmental profiles of cancer nucleosomes. The platform detects and measures circulating nucleosomes and transcription factors with potential to be tissue specific, and therefore cancer specific. If successful, the platform could result in a simple blood test for multiple cancers.
The biotech firm is using these tools to expand diagnostic developments that focus on circulating DNA fragment analysis, to a broader and potentially more powerful investigation of the epigenetic status of a patient's circulating chromosome fragments, in addition to its ongoing work with its assay-based format in a range of cancers.
Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore.
Contact Angela at [email protected]
Follow her on Twitter @AHarmantas